Lilly(Eli) & Co

+12.92 (+4.13%)

FDA Approves Lilly And Incyte's Olumiant® (Baricitinib) As First And Only Systemic Medicine For Adults With Severe Alopecia Areata

Published: 06/14/2022 02:03 GMT
Lilly(Eli) & Co (LLY) - :fda Approves Lilly and Incyte's Olumiant® (baricitinib) As First and Only Systemic Medicine for Adults With Severe Alopecia Areata.
Lilly Also Expects Regulatory Decisions for Olumiant in Aa in European Union and Japan in 2022.